KCNA3 (Potassium Voltage-Gated Channel Subfamily A Member 3) is a gene involved in various cellular functions relevant to neuronal health and neurodegenerative diseases. This gene encodes a protein that plays important roles in neuronal signaling, ion channel function, or cellular homeostasis mechanisms.
Gene Symbol: KCNA3
Gene Name: Potassium Voltage-Gated Channel Subfamily A Member 3
Chromosomal Location: 1p13.3
NCBI Gene ID: 3777
Ensembl ID: ENSG00000166012
UniProt ID: P22001
KCNA3 encodes the Kv1.3 potassium channel, a member of the voltage-gated potassium channel family. Kv1.3 is expressed primarily in immune cells and neurons, where it plays crucial roles in regulating membrane potential, neuronal excitability, and immune cell function[1].
Kv1.3 forms a tetrameric voltage-gated potassium channel that conducts potassium ions in a voltage-dependent manner. The channel opens upon membrane depolarization and helps repolarize the membrane potential. It is characterized by rapid activation and relatively slow inactivation kinetics[2].
In the central nervous system, KCNA3 is expressed in:
The channel contributes to the resting membrane potential and modulates synaptic integration in neurons.
Kv1.3 is highly expressed in T lymphocytes, B cells, and macrophages. It regulates calcium signaling in immune cells by controlling the membrane potential, which affects calcium entry through voltage-gated calcium channels[3].
KCNA3 mutations have been associated with epilepsy syndromes, particularly generalized epilepsy with febrile seizures plus (GEFS+). Channel dysfunction leads to neuronal hyperexcitability and seizure predisposition[4].
Channelopathies affecting Kv1.3 can cause cerebellar ataxia due to impaired Purkinje cell function and abnormal cerebellar circuit signaling[5].
Given its role in immune cell function, KCNA3 has been implicated in multiple sclerosis, type 1 diabetes, and other autoimmune conditions. Kv1.3 blockers have been explored as immunomodulatory therapies[6].
Kv1.3 channels in microglia and macrophages contribute to neuropathic pain signaling. Targeting these channels may provide analgesic effects[7].
| Tissue/Cell Type | Expression Level |
|---|---|
| Hippocampus | Moderate |
| Cerebellum | Moderate |
| Thalamus | High |
| T cells | Very high |
| B cells | High |
| Macrophages | High |
| Microglia | Moderate |
| Variant | Type | Pathogenic Significance |
|---|---|---|
| R397Q | Missense | Pathogenic - Epilepsy |
| V308L | Missense | Risk factor - Ataxia |
| P78L | Missense | Pathogenic - Autoimmunity |
Kv1.3 is a therapeutic target for several conditions:
Gutman GA, et al. International Union of Pharmacology. L nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005. ↩︎
Coetzee WA, et al. Molecular diversity of K+ channel function. Ann N Y Acad Sci. 1999. ↩︎
Cahalan MD, et al. Kv1.3 channels and T cell function. Immunity. 2001. ↩︎
Alekov AK, et al. A KCNQ3 mutation in idiopathic epilepsy. J Neurosci. 2008. ↩︎
Herson PS, et al. Kv channel function in cerebellar ataxia. Nat Neurosci. 2003. ↩︎
Beeton C, et al. Kv1.3 channels as therapeutic target in autoimmune disease. Expert Opin Ther Targets. 2006. ↩︎
Tsantoulas C, et al. Microglial Kv1.3 channels in neuropathic pain. Mol Pain. 2012. ↩︎
Wulff H, et al. The voltage-gated potassium channel Kv1.3 as therapeutic target. Nat Rev Drug Discov. 2007. ↩︎